Pathogenic autoantibodies and their antigens

Pathogenic autoantibodies are immunoglobulins produced by the immune system that mistakenly target and react with the body's own tissues and organs, known as autoantigens. This breakdown in self-tolerance leads to a wide range of autoimmune diseases, where the binding of these antibodies to their specific antigens causes inflammation, tissue damage, or functional interference, such as blocking receptors or activating the complement cascade (StatPearls, 2023). Therapeutic interventions often focus on depleting these antibodies from circulation, inhibiting their production by B cells, or blocking their interaction with neonatal Fc receptors (FcRn) to accelerate their degradation (Nature Reviews Drug Discovery, 2022). Understanding the specific antigen-antibody pairs is crucial for diagnosing and treating conditions such as systemic lupus erythematosus, myasthenia gravis, and neuromyelitis optica (NIH, 2021). These molecules serve as both the drivers of pathology and essential biomarkers for disease activity and treatment response.

Other names

AutoantibodiesSelf-antigensAutoantigensPathogenic immunoglobulinsSelf-reactive antibodies

Therapeutic strategies include the depletion of B-lineage cells to halt autoantibody production, the blockade of the neonatal Fc receptor (FcRn) to accelerate the catabolism of pathogenic IgG, and the use of high-dose intravenous immunoglobulin (IVIG) to saturate clearance mechanisms and provide anti-idiotypic neutralization (Nature Reviews Rheumatology, 2020).